Said Farschtschi
Overview
Explore the profile of Said Farschtschi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Age-Adapted Diagnostic Evaluation and Treatment of Patients With Type I Neurofibromatosis in Germany
Farschtschi S, Vaassen P, Kluwe L, Hartung T, Salamon J, Rosenbaum T
Dtsch Arztebl Int
. 2025 Jan;
Forthcoming.
PMID: 39773869
Background: Neurofibromatosis type 1 (NF1) is a rare genetic disorder affecting multiple bodily systems that predisposes to the development of tumors. It affects approximately 1 in 3000 newborns in Germany....
2.
Lawson McLean A, Loschner D, Farschtschi S, Dengler N, Rosahl S
Orphanet J Rare Dis
. 2025 Jan;
20(1):4.
PMID: 39762911
Background: NF2-related schwannomatosis (NF2) is associated with various tumors of the central and peripheral nervous system. There is a wide range of disabilities these patients may suffer from and there...
3.
Ristow I, Apostolova I, Kaul M, Stark M, Zapf A, Schmalhofer M, et al.
EJNMMI Res
. 2024 Dec;
14(1):127.
PMID: 39729173
Background: To intraindividually compare the diagnostic performance of positron emission computed tomography (F-18-FDG-PET/CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) in a non-inferiority design for the discrimination of peripheral nerve sheath...
4.
Schmalhofer M, Farschtschi S, Kluwe L, Mautner V, Adam G, Well L, et al.
Orphanet J Rare Dis
. 2024 Nov;
19(1):412.
PMID: 39497113
Background: Patients with neurofibromatosis type 1 (NF1) can develop plexiform neurofibromas (PN). Large tumor burden is a predictor for the development of malignant peripheral nerve sheath tumors. Whole-body magnetic resonance...
5.
Sunder-Plassmann V, Azizi A, Farschtschi S, Gruber R, Hutterer M, Ladurner V, et al.
Wien Klin Wochenschr
. 2024 Sep;
PMID: 39264447
Background: Neurofibromatosis type 1 (NF1) is a rare autosomal dominant tumor predisposition syndrome with a birth prevalence of approximately 1 in 2000-3000 individuals. Management of both benign and malignant tumors...
6.
Ristow I, Kaul M, Stark M, Zapf A, Riedel C, Lenz A, et al.
Neurooncol Adv
. 2024 Mar;
6(1):vdae021.
PMID: 38468867
Background: Neurofibromatosis type 1 (NF1) is associated with the development of benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumors. Recently described atypical neurofibromas (ANF) are considered pre-malignant precursor lesions...
7.
Ozden C, Mautner V, Farschtschi S, Molwitz I, Ristow I, Bannas P, et al.
J Neuroimaging
. 2023 Nov;
34(1):138-144.
PMID: 37942683
Background And Purpose: Thalamic hypometabolism is a consistent finding in brain PET with F-18 fluorodeoxyglucose (FDG) in patients with neurofibromatosis type 1 (NF1). However, the pathophysiology of this metabolic alteration...
8.
Kresbach C, Dottermusch M, Eckhardt A, Ristow I, Paplomatas P, Altendorf L, et al.
Neuro Oncol
. 2023 Mar;
25(9):1644-1655.
PMID: 36866403
Background: Plexiform neurofibromas can transform into atypical neurofibromas (ANF) and then further progress to aggressive malignant peripheral nerve sheath tumors (MPNST). ANF have been described to harbor distinct histological features...
9.
Carton C, Evans D, Blanco I, Friedrich R, Ferner R, Farschtschi S, et al.
EClinicalMedicine
. 2023 Jan;
56:101818.
PMID: 36684394
Background: Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder, predisposing development of benign and malignant tumours. Given the oncogenic potential, long-term surveillance is important in patients with NF1. Proposals...
10.
Godel T, Baumer P, Farschtschi S, Hofstadler B, Heiland S, Gelderblom M, et al.
Diagnostics (Basel)
. 2022 Apr;
12(4).
PMID: 35453828
Purpose To examine the spatial distribution and long-term alterations of peripheral nerve lesions in patients with schwannomatosis by in vivo high-resolution magnetic resonance neurography (MRN). Methods In this prospective study,...